Telehealth company His & Hers announced a “strategic shift” in its business model on Monday, partnering with pharmaceutical company Novo Nordisk to sell its blockbuster GLP-1 drug and stopping selling long-advertised “copycat” compounded versions. In a press release, Hims & Hers said it would “no longer advertise mixed GLP-1 offerings…”
Please follow and like us:
